Development of Drug Sensitivity Modulators and Predictive Markers of Therapeutic Response in Triple Negative Breast Cancer

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K16418
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Osaka City University
• Principal Investigator: TAKAHASHI KATSUYUKI 大阪市立大学, 大学院医学研究科, 薬剤部職員 (10597751)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: トリプルネガティブ乳癌 / 分子シャペロン / 抗がん剤感受性

Outline of Final Research Achievements

Breast cancer is a type of cancer that can be expected to have a prolonged prognosis with appropriate treatment. However, triple negative breast cancer (TNBC) accounts for about 20% of breast cancers and is a poor prognosis subtype. Therefore, the development of drug target molecules that increase sensitivity to anticancer drugs and biomarkers that predict the efficacy of anticancer drugs is much needed. Therefore, we hypothesized that Hsp72 client proteins in TNBC may play an important role in drug resistance.
We identified several target molecules, but were unable to obtain consistent results. These results suggest that the expression profile of Hsp72 may determine whether Hsp72 client proteins affect drug sensitivity.

Free Research Field

腫瘍学

Academic Significance and Societal Importance of the Research Achievements

トリプルネガティブ乳がんの薬物治療の選択肢は殺細胞性抗癌剤のみであり、予後不良なサブタイプである。そのため、抗がん剤の感受性を高める薬剤の標的分子や抗がん剤の効果を予測するバイオマーカの開発が切望されており、候補分子が明らかとなれば、癌研究・医療に多大な貢献をもたらすことが期待できる。 今回の結果は一貫した結果は得られなかったが、その理由がHsp72の発現プロファイルによるものと考えらることから、今後はHsp72の発現比較を実施し、発現亢進がみられる細胞株での再解析により真の候補分子が見いだされることが期待できる。